Press Releases

Date Title
Toggle Summary Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma
– Median OS of 15.4 months, median PFS of 5.9 months and ORR of 50% observed in recurrent/metastatic HRAS mutant HNSCC – – Outcomes with approved therapies are poor, with reported median OS of 5-8 months, PFS of 2-3 months and ORR of 13-16% in the second line – – Compelling single-agent activity
Toggle Summary Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program
– Oral presentation to highlight clinical data for tipifarnib in HRAS mutant solid tumors, including overall survival data in head and neck squamous cell carcinoma – SAN DIEGO , May 13, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed
Toggle Summary Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
SAN DIEGO , May 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of
Toggle Summary Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020
SAN DIEGO , May 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the BofA Securities Virtual Healthcare Conference
Toggle Summary Kura Oncology Announces Pricing of $125 Million Public Offering of Common Stock
SAN DIEGO , May 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 9,100,000 shares of
Toggle Summary Kura Oncology Announces Commencement of Public Offering of Common Stock
SAN DIEGO , May 05, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has commenced an underwritten public offering, subject to market
Toggle Summary Kura Oncology Reports First Quarter 2020 Financial Results
– Enhanced focus on tipifarnib in HRAS mutant HNSCC and KO-539 menin inhibitor in NPM1-mutant and KMT2A(MLL)-rearranged AML – – Three abstracts accepted for presentation at ASCO, including mature data from Phase 2 study of tipifarnib in HRAS mutant HNSCC – – $216.9 million in cash, cash equivalents
Toggle Summary Kura Oncology to Report First Quarter 2020 Financial Results
SAN DIEGO , April 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report first quarter 2020 financial results after the close of
Toggle Summary Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas
– Second Fast Track designation for tipifarnib further highlights potential for tipifarnib to address unmet need for patients – – Company plans to initiate a registration-directed trial of tipifarnib in advanced nodal lymphomas of TFH phenotype, including AITL, in second half of 2020 – SAN DIEGO ,
Toggle Summary Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results
– Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas anticipated to complete enrollment in first quarter of 2021 – – Company preparing to initiate a registration-directed trial of tipifarnib in T-cell lymphomas following positive feedback from FDA – –